The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.
about
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantTamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerAre current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationGrape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profilesTyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER).A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogenAmphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer.A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesisClinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancerTherapies for triple negative breast cancer.Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.
P2860
Q26741153-26691472-F494-4EE6-91CD-32E63C27686AQ28076777-BADC9D7F-DD41-4FA8-83E1-309A46CE0E66Q28481232-AFF3E209-EE5A-409E-A97A-6356C50F5A9CQ33555585-D7454FDC-6F89-4A19-A45C-D7836A5A16D4Q33612070-9A2E5722-C5C2-4992-9CAD-D0E370B6E11EQ34855692-32ED4217-229F-4260-886C-ECE3C62B19FBQ35889673-EFCE5FB5-DEDE-4446-A3BB-112734387437Q35955297-3BBB027E-E570-4092-9E6E-8D5F75FBD8D6Q36059078-C595D0F8-8FC2-40AD-8B57-AB3E373A7D4DQ36296553-F27B7C1E-A5E1-4A16-BE94-9AE0D6B8391EQ36653598-3C42A6EC-8800-48BE-B6D2-F8E4D8AF1519Q37270040-20E0B555-0E00-40D4-8E6F-19F82BE5CC26Q37356307-222C7D43-03A8-4549-AFD5-E152C416A2B0Q38424397-FDFF2A68-8B97-4DBB-9240-BB48285E1609Q49250031-273881A8-DAC6-47C9-B038-F629D559E949
P2860
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The effects of gefitinib in ta ...... east cancer: a phase II study.
@en
The effects of gefitinib in ta ...... east cancer: a phase II study.
@nl
type
label
The effects of gefitinib in ta ...... east cancer: a phase II study.
@en
The effects of gefitinib in ta ...... east cancer: a phase II study.
@nl
prefLabel
The effects of gefitinib in ta ...... east cancer: a phase II study.
@en
The effects of gefitinib in ta ...... east cancer: a phase II study.
@nl
P2093
P2860
P356
P1476
The effects of gefitinib in ta ...... reast cancer: a phase II study
@en
P2093
Amit Agrawal
Eleanor Gutteridge
John Robertson
Robert Nicholson
P2860
P304
P356
10.1002/IJC.24884
P577
2010-04-01T00:00:00Z